Foghorn Therapeutics Inc. announced the FDA has placed the Phase I dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia and myelodysplastic syndrome on a partial clinical hold.
[Foghorn Therapeutics, Inc. (BioSpace, Inc.)]
